News

Sanofi outlines high single-digit sales growth for 2025 while advancing innovation pipeline and strategic acquisitions
Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the ...
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.
Sanofi falls after Q2 profit misses despite sales beat on higher costs
Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...
The Pharma Letter6h
Sanofi shares slide as income stalls
Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...
Zacks.com on MSN2d
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...
Zacks Investment Research on MSN6h
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...
Medscape6d
Why Are RSV Vaccine Rates so Shockingly Low?
Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...
Physician's Weekly4d
Understanding Parental Views on RSV and Childhood Vaccines
Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...
pharmaphorum5d
Mpox shows need for new approaches to therapeutic antibody research
A successful example of these technologies coming together is Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip), an anti-RSV monoclonal antibody approved for the prevention of RSV in infants.